Generic Drugs

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

By

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.

GSK accused of wrongdoing in Poland, Wellbutrin generic revoked

Poland joins the list of countries in which GlaxoSmithKline is accused of misconduct. Meanwhile, bioequivalence issues have prompted the FDA to revoke its approval of GSK's Wellbutrin generic.

Sun Pharma to buy Ranbaxy

The announcement will create the fifth largest generics drug maker, reports Reuters.

In DC, parties argue generic label freedom

In DC, parties argue generic label freedom

By

At a hearing today, Public Citizen and the generics industry are sounding off on an FDA proposal that would allow generics firms to update labels, regardless of whether the brand has or hasn't.

FDA says generics study is wrong

The regulator disputes findings that generic heart drugs made abroad were contaminated.

Color keeps GSK generic off the market

GlaxoSmithKline claims that Sandoz needs to change the packaging for its generic Advair.

Novartis not sweating generics turmoil

The drugmaker's CEO tells Reuters it is in a good position to weather troubles in India's generics industry.

Teva converts Copaxone users

The drugmaker's outreach efforts involve switching patients to the latest—and patented—Copaxone formulation.

Proposed budget gets mixed reviews

The White House's proposed FY 2015 budget gives an additional 1% to the FDA.

FDA ends Teva Plan B OTC dominance

The regulator is allowing generic makers room on the OTC contraceptive shelf.

FDA slammed over generics

Critics say the FDA is not doing enough to ensure generics quality and that communications between industry and the regulator need to improve.

Ranbaxy shuts two sites

The drugmaker says the voluntary measure was out of an abundance of caution.

FDA launched stealth drug testing op

The regulator kicked off a $20-million generics testing project in September.

Ranbaxy, Teva settle with New York State

The drugmakers admitted no wrongdoing, but are paying the state $300,000 over an agreement not to challenge generics filings.

Actavis buys Forest, bolsters specialty biz

Actavis buys Forest, bolsters specialty biz

By

The drugmaker, hitherto known for its generic expertise, says the purchase could mean that half its future revenue will come from branded, specialty drugs.

Must biosimilar names be distinct? No, experts argue

Must biosimilar names be distinct? No, experts argue

Innovator companies want the FDA to adopt separate names for biosimilars. Manufacturing changes aren't drastic enough to make it necessary, experts argued at an FTC workshop.

FDA bans another Ranbaxy plant

FDA found workers were manipulating test data.

Judge: Teva not liable for Oxycontin patent violation

Purdue Pharma says it will appeal.

Re-org for Actavis specialty brands business

The generics giant is splitting the business into four separate units with a newly appointed leader running each.

Patent cliff a drag on 2012 health spend

Patent cliff a drag on 2012 health spend

By

Generics accounted for almost 75% of dispensed drugs in 2012, according to CMS researchers.

2014 shaping up to be bridge year for Lilly

2014 shaping up to be bridge year for Lilly

By

The company's guidance aligns with expectations that 2014 will be a nail-biter.

Sandoz wades into Humira biosimilars

The generics maker says an adalimumab biosimilar would anchor its immunology portfolio.

Teva unclear on 2014 future

The company released two financial scenarios. The key is generic Copaxone.

E-prescribing systems not so pharma friendly

E-prescribing systems not so pharma friendly

By

A study points out barriers to e-prescribing pharma products and shows how doctors rate various EHRs.

Study shows how brand Rx drain Medicare

ProPublica's deep-dive into Medicare brand-prescribing habits show brands make a dent in Medicare's budget.

IMS predicts $1T global drug market by 2017

IMS predicts $1T global drug market by 2017

By

The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.

FDA proposal puts generics, brands on equal footing

The proposed change would allow generics makers to update labels even if branded drugmakers do not, possibly opening up generics to new liability issues.

Study shows swift move from brand to generic drugs

Study shows swift move from brand to generic drugs

By

Researchers say it's not just payers supporting the switch, and all ages appear to be brand agnostic.

Email Newsletters